Belgium Patent System

Belgium's most distinctive IP advantage is geographic: Brussels is the de facto capital of the European Union — the seat of the European Commission, the Council of the EU, and the European Parliament. This concentration of EU institutional power has direct IP implications: (1) EU IP policy proximity: EU pharmaceutical patent linkage reform, SPC reform proposals, data exclusivity debates, compulsory licensing regulations, and the EU Supplementary Protection Certificate system are all legislated and debated in Brussels. Belgian law firms, IP practices, and in-house counsel in Brussels have unique proximity to EU IP legislative processes, allowing them to influence policy and anticipate changes before they become law; (2) European Patent Office Hague branch: the EPO's branch in The Hague (technically in the Netherlands, 200km from Brussels) is the EPO's second-largest location, processing significant European patent applications across multiple technical fields. The geographic proximity benefits Belgian applicants and practitioners; (3) UPC Brussels Local Division: the UPC Local Division in Brussels handles patent infringement and validity disputes for Belgium (and Luxembourg). Given Belgium's role as the EU's capital, Brussels UPC proceedings are likely to attract cases involving pan-European pharmaceutical and technology patent disputes where EU-wide commercial impact is at stake; (4) World Intellectual Property Organization (WIPO): while WIPO is headquartered in Geneva (Switzerland), Belgium hosts important WIPO-adjacent activities given Brussels' role as the EU's representation point for TRIPS/WTO IP negotiations. EU member states coordinate IP policy with WTO through the European Commission, which is based in Brussels; (5) Belgian pharmaceutical regulatory environment: Belgium hosts Sciensano (Belgian Institute for Public Health) and FAMHP (Federal Agency for Medicines and Health Products — FAMHP/AFMPS) which issue marketing authorizations for medicinal products in Belgium. The FAMHP authorization date is the relevant date for Belgian SPCs (EU SPC Regulation directly applies); (6) International arbitration: Brussels hosts the ICC International Court of Arbitration's Brussels secretariat and the Brussels-based CEPANI (Belgian Centre for Arbitration and Mediation) — international IP disputes are regularly resolved in Brussels through arbitration.

Belgium is disproportionately important for the global pharmaceutical industry — one of the highest concentrations of biopharma companies per capita in Europe: (1) UCB S.A. (Brussels — biologic drugs: Cimzia [certolizumab pegol], Bimzelx [bimekizumab]; neurology: Vimpat [lacosamide — voltage-gated sodium channel blocker], Briviact [brivaracetam], Keppra [levetiracetam]; biosimilars [UCB has been exploring biosimilar development]); (2) Galapagos NV (Mechelen — biopharmaceutical R&D; collaboration with Gilead Sciences; JAK inhibitor filgotinib [Jyseleca]; early pipeline patents in fibrosis, oncology; notable Gilead partnership structure — multi-billion dollar upfront payments for access to Galapagos's drug discovery platform); (3) Argenx SE (Ghent — FcRn antagonist efgartigimod [Vyvgart] for myasthenia gravis; novel neonatal Fc receptor targeting approach; strong patent portfolio in FcRn biology); (4) iTeos Therapeutics (Brussels — immuno-oncology, acquired by GSK for $1.9B in 2021; EOS-448 anti-TIGIT antibody); (5) Janssen Pharmaceutica NV (Beerse — Johnson & Johnson's Belgian subsidiary; one of the world's most important pharmaceutical R&D centres; HIV drugs [darunavir/Prezista, rilpivirine/Edurant], antipsychotics [esketamine/Spravato], oncology [ibrutinib/Imbruvica co-developed with Pharmacyclics/AbbVie, daratumumab/Darzalex co-developed with Genmab]; Beerse R&D campus employs thousands of scientists; major EP and US patent filer); (6) KU Leuven (Katholieke Universiteit Leuven — technology transfer office LRD; significant biotech and pharmaceutical patent portfolio from fundamental research; spin-off companies including Ablynx [nanobodies — camelid antibody-derived single-domain antibodies], later acquired by Sanofi; VIB [Flanders Institute for Biotechnology] — premier Flemish biotech research institute with extensive patent portfolio).

BOIP (Benelux Office for Intellectual Property / Bureau Benelux de la Propriété Intellectuelle / Benelux Merkenbureau, headquartered in The Hague, Netherlands) is the joint intellectual property office for the three Benelux countries — Belgium, Netherlands, and Luxembourg — but it handles only trademarks and designs, NOT patents. For Benelux trademarks: BOIP registers and administers Benelux trademarks (Benelux word marks, figurative marks, combined marks, and three-dimensional marks) that take automatic effect in all three Benelux countries (Belgium, Netherlands, Luxembourg) as a single unitary Benelux trademark right. A Benelux trademark provides protection in all three countries with one application, one examination, and one renewal fee. For Benelux designs: BOIP registers Benelux industrial designs (two-dimensional graphic designs and three-dimensional product designs) that take automatic effect in all three countries. For Belgian patents: patents are NOT processed by BOIP. Belgian national patent applications are filed with the CBE — the Belgian IP Office (Office belge de la Propriété intellectuelle / Belgisch Bureau voor de Intellectuele Eigendom), which operates within the Federal Public Service Economy (Service public fédéral Economie / Federale Overheidsdienst Economie). For European patents, applicants file with the EPO and validate in Belgium through the CBE. Many foreign applicants seeking patent protection in Belgium file a European patent application with the EPO (filing in Munich, The Hague [EPO branch], or Berlin) and then validate the granted EP patent in Belgium by paying Belgian validation fees and filing a French or Dutch translation. The EPO's branch in The Hague (Netherlands), adjacent to BOIP, is a common point of confusion — EPO The Hague handles European patent applications, while BOIP handles Benelux trademarks and designs.

IMEC (Interuniversity Microelectronics Centre / Imec vzw, Leuven, Belgium) is consistently ranked as the world's leading research institute for microelectronics and nanoelectronics, with a unique position at the intersection of academic research and industrial semiconductor development. Founded in 1984 with backing from the Flemish government and the Catholic University of Leuven (KU Leuven), IMEC pioneered the open-innovation model for semiconductor research — industry partners pay membership fees and participate in joint research programs, receiving access to IMEC's research results and IP while contributing their own resources. Why IMEC is globally unique: (1) EUV lithography leadership: IMEC has been the world's primary research venue for extreme ultraviolet (EUV) lithography — the technology enabling chip manufacturing at 7nm, 5nm, 3nm, and sub-2nm feature sizes. ASML (the Dutch company that produces virtually all EUV lithography machines) has worked with IMEC on EUV process development for decades. The EUV patterning IP generated at IMEC underpins advanced chip manufacturing at TSMC, Samsung Foundry, and Intel Foundry; (2) Industrial partnership model: IMEC's 'core programs' bring together the world's leading chip manufacturers (TSMC, Samsung, Intel, Qualcomm), equipment suppliers (ASML, Lam Research, Applied Materials, Tokyo Electron), and materials suppliers (JSR, Merck, Dow) in pre-competitive research on advanced chip technologies. Each partner gets access to research results under the joint program IP framework; (3) IP licensing: IMEC licenses its patents to industry participants, generating royalty revenues that fund its research. IMEC's patent portfolio in advanced lithography, 3D integration, compound semiconductors, MEMS, and photonics is commercially significant; (4) Spin-offs: IMEC has generated numerous spin-off companies including Vastigo, X-FAB Silicon Foundries (semiconductor foundry), and others, each carrying IMEC-derived IP into commercialization; (5) Medical technology: IMEC's wearable health monitoring research (ECG chips, biopotential sensors, neural interfaces for brain-computer interfaces) has generated patents and spin-off companies in the digital health space.

Belgium, as an EPC contracting state, follows the EPC's absolute novelty standard — there is NO general grace period for Belgian national patents or for European patents (EP) validated in Belgium. Any public disclosure of the invention before the patent application filing date destroys novelty permanently. The only exception is EPC Article 55, which provides that a prior disclosure does not destroy novelty if: the disclosure occurred within 6 months before the European patent application filing date (or before the date of the priority application), AND the disclosure was due to evident abuse in relation to the applicant or predecessor in title, OR the disclosure was at an officially recognized international exhibition (a specific category of world's fairs/expositions recognized under the Paris Convention on International Exhibitions). This EPC Art. 55 exception is extremely narrow. A Belgian inventor who publishes a journal article, presents at a scientific conference, posts on social media, pitches to investors, shows a prototype at a trade fair, or publicly demonstrates an invention — any of these disclosures will destroy Belgian and European patent novelty permanently. There is no 'one-year' or other grace period safety net as exists under US AIA § 102(b)(1). Critical warning for Belgian-US commercial situations: Belgian biotech and pharma researchers regularly publish academic papers or present at conferences before patent filing. If publication in Nature, Cell, The Lancet, or any other scientific journal occurs before a European patent application is filed, European patent rights are irretrievably lost — only US rights survive (under the 12-month US AIA grace period). Companies commercializing Belgian university research should establish clear IP protection procedures requiring patent filing before any academic publication or conference presentation.

UCB S.A. (Brussels) employs a sophisticated multi-layer patent protection strategy for its biologic drug products, particularly certolizumab pegol (Cimzia) and bimekizumab (Bimzelx). Certolizumab pegol (Cimzia) patent strategy: Certolizumab pegol is structurally unusual — it is a PEGylated Fab' fragment of a humanized anti-TNF antibody, not a complete antibody molecule. This structural distinctiveness shaped UCB's IP strategy: (1) The Fab' structure: unlike infliximab (Remicade), adalimumab (Humira), and etanercept (Enbrel), certolizumab pegol lacks an Fc region — it does not trigger antibody-dependent cellular cytotoxicity (ADCC) or fix complement. Patents cover the Fab' fragment structure and its therapeutic advantages; (2) PEGylation patents: the PEGylation of the Fab' fragment (attachment of polyethylene glycol chains to reduce renal clearance and extend half-life) is protected by specific composition-of-matter and method patents covering the PEGylation chemistry, the specific PEG molecular weights used, and the conjugation chemistry; (3) Manufacturing process patents: the fermentation, purification, and PEGylation manufacturing process for certolizumab pegol — developed at UCB Biopharma's Braine-l'Alleud manufacturing facility — is protected by process patents; (4) Indication patents: specific therapeutic use patents cover certolizumab pegol's use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and other approved indications. Bimekizumab (Bimzelx) patent strategy: bimekizumab is a novel IL-17A/F dual inhibitor — a single monoclonal antibody that blocks both IL-17A and IL-17F simultaneously. UCB's patent strategy here focuses on: the dual-specificity of the antibody for both IL-17A and IL-17F; the CDR sequences (antibody sequence patents); the mechanism of action and therapeutic benefits of dual inhibition over IL-17A-only inhibitors (Cosentyx/secukinumab, Taltz/ixekizumab); method of treatment patents for psoriasis, psoriatic arthritis, and axial spondyloarthritis at specific doses and regimens.

The UPC Local Division in Brussels handles patent infringement and validity disputes for Belgium (and Luxembourg, which shares the Brussels seat). Key features of the Brussels UPC Local Division: (1) Jurisdiction: the Brussels UPC Local Division has jurisdiction over infringement actions where the infringement occurred in Belgium or Luxembourg, and over invalidity/revocation counterclaims in those actions. It can issue pan-European injunctions, orders for seizure, and declarations of non-infringement for Unitary Patents and European patents with unitary effect, with enforcement in all UPC participating EU member states; (2) Language of proceedings: proceedings at the Brussels UPC Local Division can be conducted in French, Dutch, German, or English — consistent with Belgium's four national languages (French, Dutch, German, and de facto English as EU lingua franca). The language flexibility reflects Brussels' multicultural EU capital status; (3) Judges: the UPC Local Division uses a panel consisting of legally qualified judges (likely Belgian judges with patent expertise) supplemented by technically qualified judges (European Patent Judges with technical backgrounds in relevant fields). The multi-judge approach combines legal and scientific expertise; (4) Significance for EU pharma: given Brussels' role as the EU capital and the headquarters of the pharmaceutical industry lobbying and regulatory affairs functions (EFPIA — European Federation of Pharmaceutical Industries and Associations is headquartered in Brussels), the Brussels UPC Local Division will likely see disputes between major pharmaceutical companies (originator vs. generic, originator vs. biosimilar manufacturer) where EU-wide commercial consequences are at stake. A Brussels UPC injunction covers Belgium and Luxembourg directly, but more importantly, a Unitary Patent infringement finding issued by any UPC Local Division is EU-wide in effect; (5) Relationship to Belgian courts: national Belgian courts (in particular, the Brussels Enterprise Court — Tribunal de l'entreprise de Bruxelles) retain jurisdiction over purely national patent disputes (Belgian national patents, pre-UPC European patents for which unitary effect was not registered). The UPC and national courts have concurrent jurisdictions during the seven-year transitional period.